Prediction of growth sensitivity of acute promyelocytic leukemia cells to granulocyte colony-stimulating factor using 7AAD/PY during administration of all-trans retinoic acid.
We discussed utility of cell cycle and phenotypic analysis of acute promyelocytic leukemia (APL) cells using 7AAD/PY for the prediction of efficacy and risks of all-trans retinoic acid (ATRA) and granulocyte colony-stimulating factor (G-CSF) administration to patients with APL. Serial changes in phenotype and cell kinetics of APL cells from two patients were analyzed during ATRA administration. CD15 and CD11b were expressed on the APL cells in vivo as neutrophil maturation markers, while growth activity of the cells was decreased during ATRA administration. Using 7AAD/PY, changes in phenotype and cell kinetics were clearly detected after 2 days of cultivation with ATRA and/or G-CSF. In one patient, APL cells harvested from marrow during the first 3 weeks of ATRA administration showed distinct growth sensitivity to G-CSF ex vivo, and the cells harvested after a 4-week exposure to ATRA appeared to have lost this sensitivity. In this patient, G-CSF could be safely administered after 4 weeks of ATRA therapy. 7AAD/PY analysis is useful for predicting growth sensitivity of APL cells to G-CSF during ATRA administration.
Toba
K
K
First Department of Internal Medicine, Niigata University, School of Medicine, Japan.
Koike
T
T
Wang
Y
Y
Nagai
K
K
Takahashi
H
H
Hashimoto
S
S
Uesugi
Y
Y
Aizawa
Y
Y
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001853:Bone Marrow / Q000473:pathology; D018826:CD13 Antigens / Q000032:analysis; D002453:Cell Cycle / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D003609:Dactinomycin / Q000031:analogs & derivatives; D004357:Drug Synergism; D017809:Fatal Outcome; D005260:Female; D005434:Flow Cytometry; D005456:Fluorescent Dyes; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology* / Q000627:therapeutic use; D016130:Immunophenotyping; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy / Q000473:pathology* / Q000628:therapy; D008297:Male; D014411:Neoplastic Stem Cells / Q000187:drug effects* / Q000473:pathology; D011754:Pyronine; D012074:Remission Induction; D016879:Salvage Therapy; D014212:Tretinoin / Q000494:pharmacology* / Q000627:therapeutic use; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; D005456:Fluorescent Dyes; D007155:Immunologic Factors; D016179:Granulocyte Colony-Stimulating Factor; D003609:Dactinomycin; D014212:Tretinoin; C025942:7-aminoactinomycin D; D018826:CD13 Antigens; D011754:Pyronine